NOMA has approved the PET imaging agent for the identification of PSMA-positive lesions in patients with prostate cancer.

Imaging agent to improve prostate cancer detection

<a href='https://grafa.com/company/telix-pharmaceuticals-ltd-10341'><a href='https://grafa.com/company/telix-pharmaceuticals-ltd-10341'>Telix Pharmaceuticals

Telix Pharmaceuticals (NASDAQ: TLX) has hit a key clinical milestone, finishing patient enrollment in its Phase 3 Illuccix Japan study of TLX591‑Px for prosta

Completed enrollment of 105 patients in Phase 3 registration study of TLX591-Px (Illuccix®) for prostate cancer imaging in Japan. The study data will be used to support a New Drug Application (NDA) for TLX591-Px in Japan. MELBOURNE, Australia and TOKYO, July 17, 2026 /PRNewswire/ -- Telix Pharm...

<a href='https://grafa.com/company/telix-pharmaceuticals-ltd-10341'>Telix Pharmaceuticals</a> <a href='https://grafa.com/asset/telix-pharmaceuticals-ltd-1034

<a href='https://grafa.com/company/telix-pharmaceuticals-ltd-10341'>Telix Pharmaceuticals</a> <a href='https://grafa.com/asset/telix-pharmaceuticals-ltd-1034

MELBOURNE, Australia and INDIANAPOLIS, Jan. 16, 2026 /PRNewswire/ — Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces that the first patient in the United States (U.S.) has been dosed in BiPASS™ (Biopsy of the Prostate Avoidance Stratification Study), a Phase 3 trial to evaluate the use of Telix’s commercial PSMA-PET[1] imaging agents, Illuccix® (kit […]

Telix Pharmaceuticals (ASX:TLX) is an asset listed on the ASX, and part of the Health Care sector. Grafa’s asset page shows Telix Pharmaceuticals’s share price,

Reported Monday, Jun 23 - 7:38am EDT (TheFly subscription required to read more.)

Reported Monday, Mar 17 - 5:55pm EDT (TheFly subscription required to read more.)

Telix Pharmaceuticals' Illuccix® PSMA-PET imaging agent has gained marketing authorization in Germany to assist in prostate cancer diagnosis, enhancing patient care.

Telix Pharmaceuticals has received approval for its PSMA-PET imaging agent, Illuccix, in France, enhancing prostate cancer diagnosis capabilities in hospitals.

Telix Pharmaceuticals announces Illuccix® gains approval in the Netherlands for detecting prostate cancer, enhancing diagnostic accuracy for patients.

Illuccix®, a groundbreaking prostate cancer imaging agent, is now officially approved in Brazil, marking a significant advancement in medical technology for Latin America.

Telix Pharmaceuticals has announced record financial results for 2024, highlighting significant revenue growth and plans for continued expansion in 2025.

Telix Pharmaceuticals has received approval for Illuccix®, enhancing prostate cancer imaging in the UK, addressing urgent patient needs.

Telix Pharmaceuticals Limited announces the approval of its prostate cancer imaging agent, Illuccix®, by European authorities, marking a significant step forward.